Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 241 - 241
Published: Feb. 12, 2025
Background/Objective:
World
Health
Organization
latest
statistics
state
that
17%
of
infectious
diseases
are
transmitted
by
vectors,
causing
more
than
700,000
deaths
each
year.
Particularly,
dengue
(DENV),
Zika
(ZIKV)
and
yellow
fever
(YFV)
viral
infections
have
generated
international
awareness
due
to
their
epidemic
proportion
risks
spread.
In
this
framework,
the
repositioning
strategy
Efavirenz
(EFV)
represents
a
key
clinical
feature
improve
different
antiviral
therapies.
Therefore,
development
Soluplus®-based
nanomicelles
(NMs)
loaded
with
EFV
(10
mg/mL)
for
optimized
oral
pharmacotherapy
against
ZIKV,
DENV
YFV
was
investigated.
Methods:
EFV-NMs
were
obtained
an
acetone
diffusion
technique.
Micellar
size
in
vitro
micellar
interaction
mucin
assessed
dynamic
light
scattering.
cytocompatibility
investigated
A549
Vero
cells
activity
evaluated.
vivo
bioavailability
histological
studies
Wistar
rats.
Results:
encapsulation
within
Soluplus®
NMs
increased
drug's
apparent
aqueous
solubility
up
4803-fold
unimodal
distribution
~90
nm
at
25
37
°C.
also
pH
range
1.2-7.5
its
storage
physicochemical
stability
4
°C
confirmed
over
2
years.
assays
dispersions
resulted
safe
nanoformulations.
Interestingly,
EFV-loaded
exhibited
significantly
higher
compared
solution
all
tested
flaviviruses.
addition,
selectivity
index
(SI)
values
reveal
considerably
biological
efficacy
cell
lines
infection
(SI
>
10).
Further,
drug
pharmacokinetics
parameters
enhanced
after
administration
NMs,
being
biocompatible
not
damage
gastrointestinal
segments.
Conclusions:
Overall,
our
nanoformulation
highlighted
potential
as
novel
delivery
platform
therapy.
Intelligent Pharmacy,
Journal Year:
2024,
Volume and Issue:
2(5), P. 721 - 722
Published: Feb. 1, 2024
Dengue
fever
is
a
mosquito-borne
illness
that
affects
millions
of
people
worldwide.
Artificial
intelligence
(AI)
being
employed
in
the
battle
against
it.
AI
used
to
analyse
dengue
immune
repertoires,
which
may
yield
hitherto
unheard-of
insights
into
complexities
adaptive
immunity,
help
development
novel
treatments,
and
influence
creation
vaccines.
This
AI-driven
strategy
contribute
therapies
are
more
potent.
Journal of Biomolecular Structure and Dynamics,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 18
Published: March 5, 2024
Dengue
fever,
a
major
global
health
challenge,
affects
nearly
half
the
world's
population
and
lacks
effective
treatments
or
vaccines.
Addressing
this,
our
study
focused
on
natural
compounds
that
potentially
inhibit
dengue
virus's
RNA-dependent
RNA
polymerase
(RdRp),
crucial
target
in
viral
replication
cycle.
Utilizing
MTiOpenScreen
webserver,
we
screened
1226
from
NP-lib
database.
This
screening
identified
four
promising
ZINC000059779788,
ZINC0000044404209,
ZINC0000253504517
ZINC0000253499146),
each
demonstrating
high
negative
binding
energies
between
−10.4
−9.9
kcal/mol,
indicative
of
strong
potential
as
RdRp
inhibitors.
These
underwent
rigorous
validation
through
re-docking
detailed
100
ns
molecular
dynamics
(MD)
simulation.
analysis
affirmed
dynamic
stability
protein-ligand
complexes,
critical
factor
effectiveness
drug
candidates.
Additionally,
conducted
essential
free
energy
landscape
calculations
to
understand
structural
transitions
protein
upon
ligand
binding,
providing
valuable
insights
into
mechanism
inhibition.
Our
findings
present
these
molecules
therapeutic
agents
against
virus.
By
targeting
allosteric
site
RdRp,
offer
novel
approach
hinder
process.
research
significantly
contributes
search
for
anti-dengue
treatments,
positioning
key
players
virus
control
strategies.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 241 - 241
Published: Feb. 12, 2025
Background/Objective:
World
Health
Organization
latest
statistics
state
that
17%
of
infectious
diseases
are
transmitted
by
vectors,
causing
more
than
700,000
deaths
each
year.
Particularly,
dengue
(DENV),
Zika
(ZIKV)
and
yellow
fever
(YFV)
viral
infections
have
generated
international
awareness
due
to
their
epidemic
proportion
risks
spread.
In
this
framework,
the
repositioning
strategy
Efavirenz
(EFV)
represents
a
key
clinical
feature
improve
different
antiviral
therapies.
Therefore,
development
Soluplus®-based
nanomicelles
(NMs)
loaded
with
EFV
(10
mg/mL)
for
optimized
oral
pharmacotherapy
against
ZIKV,
DENV
YFV
was
investigated.
Methods:
EFV-NMs
were
obtained
an
acetone
diffusion
technique.
Micellar
size
in
vitro
micellar
interaction
mucin
assessed
dynamic
light
scattering.
cytocompatibility
investigated
A549
Vero
cells
activity
evaluated.
vivo
bioavailability
histological
studies
Wistar
rats.
Results:
encapsulation
within
Soluplus®
NMs
increased
drug's
apparent
aqueous
solubility
up
4803-fold
unimodal
distribution
~90
nm
at
25
37
°C.
also
pH
range
1.2-7.5
its
storage
physicochemical
stability
4
°C
confirmed
over
2
years.
assays
dispersions
resulted
safe
nanoformulations.
Interestingly,
EFV-loaded
exhibited
significantly
higher
compared
solution
all
tested
flaviviruses.
addition,
selectivity
index
(SI)
values
reveal
considerably
biological
efficacy
cell
lines
infection
(SI
>
10).
Further,
drug
pharmacokinetics
parameters
enhanced
after
administration
NMs,
being
biocompatible
not
damage
gastrointestinal
segments.
Conclusions:
Overall,
our
nanoformulation
highlighted
potential
as
novel
delivery
platform
therapy.
